Ticker
Reporting Basis
Period
From
To
Form Type
Report Format
Update Type

UTD THERAPEUTIC   FYE=12 (December)

Annual - Income Statement - Company Specific

Fiscal period2024202320222021202020192018201720162015
Period End Date12/31/202412/31/202312/31/202212/31/202112/31/202012/31/201912/31/201812/31/201712/31/201612/31/2015
Service sales--------------------
License fees--------------------
Net product sales2,877.402,327.501,936.301,685.501,483.301,448.801,627.801,725.301,598.801,460.57
Service sales to affiliates--------------------
Other revenues--------------0.00--5.19
Grant revenue--------------------
Total Revenues2,877.402,327.501,936.301,685.501,483.301,448.801,627.801,725.301,598.801,465.76
Cost of product sales309.70257.50151.60122.50108.10117.60198.70105.7072.7069.04
Cost of service sales--------------------
Research and development481.00408.00322.90540.10357.701,182.60357.90264.60147.60245.10
Selling, general and administrative709.70477.10482.10467.00423.90336.20265.80330.10316.80452.61
Sales and marketing--------------------
Impairment of HeartBarĀ® trade name--------------------
Settlement of loss contingency----------0.000.00(210.00)----
Total Operating Expenses1,500.401,142.60956.601,129.60889.701,636.40--910.40537.10--
Operating Income (Loss)1,377.001,184.90979.70555.90593.60(187.60)805.40814.901,061.70699.02
Interest expense42.9059.3032.4018.6023.5044.2013.909.003.904.74
Write-down of investment--------------------
Impairment of cost method investment----------0.0053.5049.60----
Impairments of investments in privately-held companies0.000.001.702.309.10----------
Gain on sale of intangible asset--------------0.00--350.00
Gain (Loss) on marketable investments--------------------
Equity loss in affiliate--------------------
Interest income199.10162.7045.2016.7028.6044.2028.60------
Other income (expense)5.80(14.00)(40.20)42.2049.3022.60(7.70)13.202.400.16
Total other (expense) income, net162.0089.40(29.10)38.0045.3022.60822.40(45.40)(1.50)766.75
Income before income tax1,539.001,274.30950.60593.90638.90(165.00)758.90769.501,060.201,044.44
Current- Foreign------------------0.81
Current: Federal--------------261.30311.90320.73
Current: State--------------23.9024.1033.98
Deferred: Federal--------------67.208.30(2.85)
Deferred: State--------------(0.80)2.207.28
Deferred: Foreign--------------------
Income tax provision (benefit)343.90289.50223.30118.10124.10(60.50)169.70351.60346.50392.80
Other Non-Current: Federal--------------------
Other Non-Current: State--------------------
Other non-current: Foreign------------------0.19
Income from Continuing Operations--------------------
Income from Discontinued Operations--------------------
Gain on disposal of discontinued operations, net of tax--------------------
Net Income (loss) Available to Common Shareholders1,195.10984.80727.30475.80514.80(104.50)589.20417.90713.70651.64
Income from continuing operations -EPS (Basic)--------------------
Discontinued operations EPS (Basic)--------------------
Net Earnings Per Share (Basic)26.4421.0415.9810.6011.65(2.39)13.549.5016.2914.17
Income from continuing operations -EPS (Diluted--------------------
Discontinued operations EPS (Diluted)--------------------
Net Earnings Per Share (Diluted)24.6419.8115.0010.0611.54(2.39)13.399.3115.2512.72
Weighted Average Shares Outstanding (Basic)45.2046.8045.5044.9044.2043.8043.5044.0043.8046.00
Weighted Average Shares Outstanding (Diluted)48.5049.7048.5047.3044.6043.8044.0044.9046.8051.22